RAPT Therapeutics Inc Stock
RAPT Therapeutics Inc Stock price
Key metrics
| Market capitalization | $127.43m |
| Enterprise Value | $-48.01m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 0.44 |
| P/B ratio (TTM) P/B ratio | 0.72 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-122.85m |
| Free Cash Flow (TTM) Free Cash Flow | $-108.69m |
| Cash position | $179.28m |
Is RAPT Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
RAPT Therapeutics Inc Stock Analysis
Analyst Opinions
6 Analysts have issued a RAPT Therapeutics Inc forecast:
Analyst Opinions
6 Analysts have issued a RAPT Therapeutics Inc forecast:
Financial data from RAPT Therapeutics Inc
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -4.06 -4.06 |
69%
69%
|
|
| EBITDA | -119 -119 |
5%
5%
|
EBIT (Operating Income) EBIT | -123 -123 |
4%
4%
|
| Net Profit | -117 -117 |
1%
1%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about RAPT Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
RAPT Therapeutics Inc Stock News
Company Profile
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
| Head office | United States |
| CEO | Brian Wong |
| Employees | 68 |
| Founded | 2015 |
| Website | rapt.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
